ALK and adenocarcinoma: Notably, 46 patients (43%) had adenocarcinoma, including two patients with epidermal growth factor receptor (EGFR) mutations, four patients with anaplastic lymphoma kinase (ALK) rearrangements, and one patient with ROS1 mutation.